MoonLake Immunotherapeutics
MLTX
$16.77
$0.040.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.47% | -26.27% | -38.25% | 12.41% | -28.86% |
| Total Depreciation and Amortization | 0.81% | 0.40% | 96.30% | 3.85% | 3.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.39% | 164.32% | -36.60% | 167.91% | -54.76% |
| Change in Net Operating Assets | -99.97% | 1,902.35% | -222.22% | 90.54% | -147.11% |
| Cash from Operations | -31.99% | 18.31% | -42.97% | 21.32% | -91.77% |
| Capital Expenditure | -- | -- | 100.00% | 80.11% | -33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -133.83% | 0.17% | 56.81% | 138.25% | -351.92% |
| Cash from Investing | -133.83% | 0.17% | 56.91% | 138.18% | -352.79% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14,982.29% | -- | -100.00% | -33.77% | 65.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | 14,982.29% | -- | -100.00% | 48,325.17% | -17.49% |
| Foreign Exchange rate Adjustments | 131.93% | -120.49% | 1,680.68% | -120.75% | 230.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -136.82% | 25.46% | -61.47% | 146.68% | -694.05% |